Cotton Mouton Diagnostics (CMD)

Year of investment

205

Business overview

Cotton Mouton Diagnostics (CMD) are the developer of a bench top instrument for endotoxin and pyrogen testing via a cost-effective and rapid testing instrument, αBET®, and accompanying consumable products. The technology allows companies within the pharmaceutical and therapeutic manufacturing industries to ensure all products released meet relevant regulatory requirements as detailed in the Pharmacopoeia. The Company was initially founded in 2014 based on technology used for the identification of malaria. However, it was later discovered that the same technology could be used for the measurement of endotoxins within pharmaceuticals. Limulus Amebocyte Lysate (LAL), a protein derived from the blood of horseshoe crabs, is the current gold standard to test for endotoxins, however, there is a strong regulatory push towards non-animal-derived recombinant reagents as the demand for endotoxin testing surges and the horseshoe crab population decreases.

CPI value creation

The market is seeing a growing need for endotoxin testing within the pharmaceutical testing market due to the expansion of therapeutic modalities and personalisation of treatment methodologies. The proven nature of the technology partnered with positive commercial traction to date alongside the applicability with newly developed recombinant reagents aligned to the changes in regulatory standards will ensure the Company remain at the forefront of the technical aspects of the market.